ATE443768T1 - Impfstoff gegen staphylokokken-vergiftung - Google Patents
Impfstoff gegen staphylokokken-vergiftungInfo
- Publication number
- ATE443768T1 ATE443768T1 AT99943610T AT99943610T ATE443768T1 AT E443768 T1 ATE443768 T1 AT E443768T1 AT 99943610 T AT99943610 T AT 99943610T AT 99943610 T AT99943610 T AT 99943610T AT E443768 T1 ATE443768 T1 AT E443768T1
- Authority
- AT
- Austria
- Prior art keywords
- staphylococco
- poisoning
- vaccine against
- aureus
- intoxication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9241698P | 1998-07-10 | 1998-07-10 | |
PCT/US1999/015569 WO2000002523A2 (en) | 1998-07-10 | 1999-07-09 | Vaccine against staphylococcus intoxication |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE443768T1 true ATE443768T1 (de) | 2009-10-15 |
Family
ID=22233100
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99941953T ATE418612T1 (de) | 1998-07-10 | 1999-07-09 | Anthrax-impfstoff |
AT99943610T ATE443768T1 (de) | 1998-07-10 | 1999-07-09 | Impfstoff gegen staphylokokken-vergiftung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99941953T ATE418612T1 (de) | 1998-07-10 | 1999-07-09 | Anthrax-impfstoff |
Country Status (7)
Country | Link |
---|---|
US (2) | US6632640B1 (de) |
EP (2) | EP1097213B1 (de) |
AT (2) | ATE418612T1 (de) |
AU (2) | AU758019B2 (de) |
CA (2) | CA2337966A1 (de) |
DE (2) | DE69940157D1 (de) |
WO (2) | WO2000002522A2 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
US7087235B2 (en) * | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
CA2337966A1 (en) * | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases | Vaccine against staphylococcus intoxication |
EP1105154B1 (de) * | 1998-08-13 | 2016-06-01 | Walter Reed Army Institute of Research | Impfstoffe gegen bakterielle superantigene |
CA2366900A1 (en) | 1999-04-16 | 2000-10-26 | Stephen J. Wisniewski | Drug delivery device comprising a dual chamber reservoir |
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
GB0016702D0 (en) | 2000-07-08 | 2000-08-23 | Secr Defence Brit | Expression system |
SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
GB0118009D0 (en) * | 2001-07-24 | 2001-09-19 | Regma Biotechnologies Ltd | Novel preparation |
US7045335B2 (en) * | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
RU2287581C2 (ru) | 2001-12-05 | 2006-11-20 | Ракеш БХАТНАГАР | Способ получения нетоксичной противосибиреязвенной вакцины |
AU2003224265A1 (en) * | 2002-04-11 | 2003-10-27 | Powderject Research Limited | Nucleic acid immunization |
US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
EP1575505A4 (de) * | 2002-09-10 | 2007-01-24 | Vical Inc | Codon-optimierte vakzine auf polynucleotid-basis gegen infektionen mit bacillus anthracis |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
JP4991108B2 (ja) * | 2002-12-13 | 2012-08-01 | アルファバックス,インコーポレイティド | 多抗原性アルファウイルス・レプリコン粒子及び方法 |
EP1608762B1 (de) * | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Verbesserte alphavirus replikons und helferkonstrukt |
WO2005034841A2 (en) * | 2003-05-14 | 2005-04-21 | Merck & Co., Inc. | Anthrax vaccine |
AU2004257214B2 (en) * | 2003-07-11 | 2010-04-22 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
EP1670505B1 (de) | 2003-09-18 | 2012-11-14 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Dna-promotor und anthrax-vakzine |
WO2005086637A2 (en) | 2004-02-11 | 2005-09-22 | Ligocyte Pharmaceuticals, Inc. | Anthrax antigens and methods of use |
KR101505496B1 (ko) | 2004-09-22 | 2015-03-25 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물 |
BRPI0609362A2 (pt) * | 2005-04-11 | 2010-03-30 | Us Gov Health & Human Serv | vetor de adenovìrus recombinante, adenovìrus recombinante, composição imunogênica e método para a produção da referida composição imunogênica |
JP5269595B2 (ja) | 2005-09-09 | 2013-08-21 | アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー | 1日1回投与用トラゾドン組成物 |
JP2009531387A (ja) | 2006-03-30 | 2009-09-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
US20070248960A1 (en) * | 2006-04-19 | 2007-10-25 | Rees Dianne M | Arrays containing cleavable RNAi molecules |
CA2689588C (en) | 2007-06-21 | 2016-08-23 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
CN101951948B (zh) | 2007-08-31 | 2015-12-09 | 芝加哥大学 | 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物 |
US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
WO2009063507A1 (en) * | 2007-11-12 | 2009-05-22 | Rakesh Bhatnagar | Dna vaccine against anthrax |
US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
BRPI0920041A2 (pt) | 2008-10-06 | 2017-06-27 | Univ Chicago | composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas |
EP3281947B1 (de) | 2009-04-03 | 2020-02-12 | The University of Chicago | Zusammensetzungen und verfahren in verbindung mit protein-a (spa)-varianten |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
US8808699B2 (en) | 2010-04-05 | 2014-08-19 | The University Of Chicago | Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response |
SG186290A1 (en) | 2010-07-02 | 2013-01-30 | Univ Chicago | Compositions and methods related to protein a (spa) variants |
EP2614074A1 (de) | 2010-09-09 | 2013-07-17 | The University of Chicago | Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen |
WO2012170097A2 (en) * | 2011-03-16 | 2012-12-13 | Regents Of The University Of Minnesota | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
EP2744517B1 (de) | 2011-08-15 | 2019-03-13 | The University of Chicago | Zusammensetzungen und verfahren in zusammenhang mit antikörpern gegen das staphylokokken-protein a |
US9968668B2 (en) | 2012-04-26 | 2018-05-15 | The University Of Chicago | Staphylococcal coagulase antigens and methods of their use |
CN104703622B (zh) | 2012-04-26 | 2017-05-24 | 芝加哥大学 | 与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法 |
JP6632974B2 (ja) * | 2013-06-19 | 2020-01-22 | インテグレイテッド バイオセラピューティクス,インコーポレイテッド | フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物 |
CA3010678A1 (en) | 2016-01-10 | 2017-07-20 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy |
US11505722B2 (en) * | 2017-06-30 | 2022-11-22 | The Boeing Company | Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials |
MX2020001046A (es) | 2017-07-27 | 2020-08-06 | Integrated Biotherapeutic Vaccines Inc | Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. |
EP3969043A1 (de) | 2019-05-15 | 2022-03-23 | Neotx Therapeutics Ltd. | Krebsbehandlung |
CN115151559A (zh) | 2019-10-02 | 2022-10-04 | 扬森疫苗与预防公司 | 葡萄球菌肽和使用方法 |
US20230085724A1 (en) | 2020-03-05 | 2023-03-23 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993014634A1 (en) * | 1992-01-28 | 1993-08-05 | National Jewish Center For Immunology And Respiratory Medicine | Protective effects of mutated superantigens |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
DE69430369T2 (de) * | 1993-09-15 | 2002-10-17 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Rekombinanter alphavirus vektor |
US5641655A (en) * | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
US5705151A (en) * | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
US5935568A (en) * | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
GB9604045D0 (en) * | 1996-02-26 | 1996-04-24 | Smithkline Beecham Plc | Novel compounds |
GB9618107D0 (en) * | 1996-08-30 | 1996-10-09 | Secr Defence | Vaccine production |
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
US6261570B1 (en) * | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
US6713284B2 (en) * | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
JP4422330B2 (ja) * | 1998-02-15 | 2010-02-24 | 財団法人化学及血清療法研究所 | 新規な免疫異常性疾患予防・治療用剤 |
WO2000000616A2 (en) * | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
CA2337966A1 (en) * | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases | Vaccine against staphylococcus intoxication |
EP1105154B1 (de) * | 1998-08-13 | 2016-06-01 | Walter Reed Army Institute of Research | Impfstoffe gegen bakterielle superantigene |
CA2354374A1 (en) * | 1998-12-07 | 2000-06-15 | U.S. Medical Research Institute Of Infectious Diseases | Live attenuated venezuelan equine encephalitis vaccine |
-
1999
- 1999-07-09 CA CA002337966A patent/CA2337966A1/en not_active Abandoned
- 1999-07-09 AT AT99941953T patent/ATE418612T1/de not_active IP Right Cessation
- 1999-07-09 US US09/350,755 patent/US6632640B1/en not_active Expired - Fee Related
- 1999-07-09 EP EP99943610A patent/EP1097213B1/de not_active Expired - Lifetime
- 1999-07-09 WO PCT/US1999/015568 patent/WO2000002522A2/en active IP Right Grant
- 1999-07-09 AT AT99943610T patent/ATE443768T1/de not_active IP Right Cessation
- 1999-07-09 AU AU55426/99A patent/AU758019B2/en not_active Ceased
- 1999-07-09 AU AU56673/99A patent/AU761021B2/en not_active Ceased
- 1999-07-09 DE DE69940157T patent/DE69940157D1/de not_active Expired - Fee Related
- 1999-07-09 DE DE69941454T patent/DE69941454D1/de not_active Expired - Fee Related
- 1999-07-09 WO PCT/US1999/015569 patent/WO2000002523A2/en active IP Right Grant
- 1999-07-09 EP EP99941953A patent/EP1097212B1/de not_active Expired - Lifetime
- 1999-07-09 CA CA002339355A patent/CA2339355A1/en not_active Abandoned
-
2003
- 2003-04-02 US US10/405,871 patent/US7374931B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69941454D1 (de) | 2009-11-05 |
AU5667399A (en) | 2000-02-01 |
AU5542699A (en) | 2000-02-01 |
WO2000002523A2 (en) | 2000-01-20 |
CA2339355A1 (en) | 2000-01-20 |
WO2000002523A9 (en) | 2000-07-27 |
US20040009183A1 (en) | 2004-01-15 |
ATE418612T1 (de) | 2009-01-15 |
US7374931B2 (en) | 2008-05-20 |
EP1097212A2 (de) | 2001-05-09 |
EP1097213B1 (de) | 2009-09-23 |
EP1097213A2 (de) | 2001-05-09 |
WO2000002523A3 (en) | 2000-11-23 |
WO2000002522A2 (en) | 2000-01-20 |
US6632640B1 (en) | 2003-10-14 |
EP1097212B1 (de) | 2008-12-24 |
AU761021B2 (en) | 2003-05-29 |
AU758019B2 (en) | 2003-03-13 |
WO2000002522A9 (en) | 2001-04-05 |
WO2000002522A3 (en) | 2000-10-12 |
DE69940157D1 (en) | 2009-02-05 |
CA2337966A1 (en) | 2000-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE443768T1 (de) | Impfstoff gegen staphylokokken-vergiftung | |
TR200806259T2 (tr) | Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler | |
HK1080506A1 (en) | Fusion proteins of mycobacterium tuberculosis | |
EA200100565A1 (ru) | Новые стрептококковые антигены | |
CY1106234T1 (el) | Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus | |
WO2003070187A3 (en) | Fusion proteins of mycobacterium tuberculosis | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
DE60130200D1 (de) | 3-cyanochinoline, 3-cyano-1,6-naphthyridine und 3-cyano-1,7-naphthyridine als protein-kinaseinhibitoren | |
BRPI0417823A (pt) | métodos para uso de bifidobactérias probióticas para animais de estimação | |
TR200202194T2 (tr) | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri | |
TR200000115T2 (tr) | Tüberkülozun immünoterapi ve teşhisi için bileşikler ve bu bileşiklerin kullanımı için yöntemler. | |
PT807178E (pt) | Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose | |
ATE382693T1 (de) | Impfstoffe gegen neurotoxine von clostridium botulinum | |
WO2005009378A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
BR0010418B1 (pt) | microorganismo de salmonella, composiÇço de vacina e uso do referido microorganismo. | |
TW200619228A (en) | Immunogenic compositions of staphylococcus epidermidis polypeptide antigens | |
ATE290548T1 (de) | Expressionsblockierung von virulenten faktoren in s. aureus | |
DK1625393T3 (da) | Vacciner, som medfører beskyttelse mod infektion af Streptococcus pneumonia | |
DE60239753D1 (de) | Impfstoff gegen infektiöses lachsanämievirus | |
AU6761301A (en) | Adjuvant composition comprising fha protein or fragment of fha protein in free form | |
AR039035A1 (es) | Proteinas con dominios tipo ig bacterianos (big) presentes en especies de leptospira | |
ITMI20031872A1 (it) | Copolimeri di poliesteri e polivinilpirrolidone. | |
AR010517A1 (es) | Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis | |
CY1108864T1 (el) | Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους | |
AU2002340731A1 (en) | Phenotype-determining virulence genes of pseudomonas aeruginosa for colonization and persistence in human beings, animals and plants, uses of said gene and associated proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |